64
Participants
Start Date
January 27, 2021
Primary Completion Date
June 7, 2022
Study Completion Date
June 7, 2022
CSL312
Fully human immunoglobulin G subclass 4/lambda recombinant monoclonal antibody
Placebo
Buffer without active ingredient
Semmelweis University, Budapest
Charité Universitätsmedizin Berlin, Berlin
Pennsylvania State University, Hershey
Institute of Asthma and Allergy, Chevy Chase
Clinical Research Center of Alabama, Birmingham
Bernstein Clinical Research Center LLC, Cincinnati
CRC Clinical Research / Hautklinik und Poliklinik der Universitätsklinik Mainz, Mainz
Universitätsklinikum Frankfurt Goethe-Universität, Frankfurt am Main
HZRM Hämophilie Zentrum Rhein Main GmbH, Mörfelden-Walldorf
AARA Research Center, Dallas
Medical Research of Arizona, Scottsdale
Raffi Tachdjian MD, Inc., Santa Monica
Allergy and Asthma Clinical Research, Walnut Creek
Barzilai University Medical Center, Ashkelon
University of Alberta - Research Transition Facility, Edmonton
Ottawa Allergy Research Corp, Ottawa
Gordon Sussman Clinical Research Inc., Toronto
Clinique specialisee en allergie de la Capitale, Québec
Universitätsklinikum Leipzig, Leipzig
Hiroshima University Hospital, Hiroshima
Kobe University Hospital, Kobe
St.Marianna University School of Medicine Hospital, Kawasaki-shi
Saitama Medical Center, Saitama
Saga University Hospital, Saga
Koga Community Hospital, Yaizu-shi
Juntendo University Hospital, Bunkyo
Saiyu Soka Hospital, Saitama
Amsterdam UMC, Location AMC, Amsterdam
Lead Sponsor
CSL Behring
INDUSTRY